Privately held Amunix Pharmaceuticals has out-licensed its T cell engager technology platform, XTEN, to Roche (OTCQX:RHHBY) aimed at discovering and developing non-oncology therapeutics against undisclosed targets.
Under the terms of the agreement, Roche will pay Amunix $40M upfront, up to $1.5B in milestones and royalties on net sales.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.